/PRNewswire/ The "Exosome Development and Manufacturing Services Market, 2022-2035" report has been added to ResearchAndMarkets.com s offering. The "Exosome.
Breast cancer affects more than one million women per year worldwide. Through this study, we develop a nanoparticle-based drug delivery system to target breast cancer cells. Aspirin has been found to inhibit thromboembolic diseases with its tumor-preventing activity. As a consequence, it relieves disease symptoms and severity. Here, mesoporous Silica Nanoparticles (MNP) have been used to deliver Aspirin to the tumor location. MNP-based Aspirin in folic acid (F)-conjugated Polydopamine (MNP-Asp-PD-PG-F) vehicles are prepared for targeted breast cancer therapy. The vehicle hinges on MNP altered with polymer polyethylene glycol (PG), polydopamine (PD), and folic acid (F). The delivery vehicle was studied for in vitro drug release, cytotoxicity and breast cancer cell proliferation. Folic Acid-conjugated drug delivery vehicles let MNPs achieve an elevated targeting efficacy, ideal for cancer therapy. It was also observed that compared to free Aspirin, our drug delivery system (MNP-Asp-PD-PG